Arrowhead

Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results

Retrieved on: 
星期四, 五月 9, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Molecule, PALISADE, EAP, American College, FCS, Risk, PIN, Hypertriglyceridemia, Arrowhead, APOC3, RNA, Webcast, Triglyceride, Cardiology, Patient, Cardiovascular disease, Diagnosis, Clinical trial, JAMA Cardiology, Amgen, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024.
  • The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m.
  • Received a $50 million milestone payment from Royalty Pharma plc, which was paid in the third quarter of fiscal 2024, following the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen.
  • Each event will feature presentations by Arrowhead team members and external key opinion leaders, who will discuss the respective disease areas and treatment landscapes.

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma

Retrieved on: 
星期四, 五月 2, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Molecule, Small RNA, AMGN, RNA interference, Risk, Partnering, Arrowhead, APOC3, Moyamoya disease, RNA, Apolipoprotein C-III, Trial, Patient, Myocardial infarction, Cardiovascular disease, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a $50 million milestone payment was received from Royalty Pharma plc (NASDAQ: RPRX).
  • This milestone was triggered after the completion of enrollment of the Phase 3 OCEAN(a) - Outcomes Trial of olpasiran, being conducted by Amgen (NASDAQ: AMGN).
  • Pursuant to its 2016 agreement with Amgen and 2022 agreement with Royalty Pharma, Arrowhead is further eligible to receive up to an additional $375 million from Amgen and $110 million from Royalty Pharma in aggregate development, regulatory, and sales milestone payments associated with olpasiran.
  • “Our pipeline of wholly owned or partnered TRiMTM-enabled candidates now includes three programs in Phase 3 - olpasiran, fazirsiran, and plozasiran.

Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences

Retrieved on: 
星期一, 四月 29, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Bank of America, Congress, DEEP, ATS, Arrowhead, Antiviral Research, RESULTS, Conference, Asthma, EAS, NLA, National Lipid Association, AN, American Thoracic Society

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
    2024 RBC Capital Markets Global Healthcare Conference – May 14-15, 2024
    BofA Securities 2024 Healthcare Conference – May 13-16, 2024
    TIDES USA 2024 – May 14-17, 2024
    American Thoracic Society (ATS) 2024 International Conference – May 17-22, 2024
    Title: A First-in-Human Study of ARO-RAGE, a Novel Inhaled RNA-Interference Therapy for Asthma
    37th International Conference on Antiviral Research (ICAR2024) – May 20-24, 2024
    European Atherosclerosis Society (EAS) 92nd Congress – May 26-29, 2024
    Title: PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR FINAL RESULTS
    Title: PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG), SHASTA-2 FINAL RESULTS
    Title: ZODASIRAN SILENCES HEPATIC ANGPTL3 LEADING TO DEEP AND DURABLE REDUCTIONS IN ATHEROGENIC LIPIDS AND LIPOPROTEINS IN MIXED DYSLIPIDEMIA PATIENTS: FINAL RESULTS FROM ARCHES-2, DOUBLE-BLIND PERIOD
    2024 National Lipid Association (NLA) Scientific Sessions – May 30 – June 2, 2024
    Title: ENCORE - PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR FINAL RESULTS
    Title: ENCORE - PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG), SHASTA-2 FINAL RESULTS
    Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars

Retrieved on: 
星期五, 四月 26, 2024
Infectious Diseases, FDA, Genetics, Diabetes, Clinical Trials, Cardiology, Biotechnology, Pharmaceutical, Health, Oncology, Arrowhead, Social media

Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: “Arrowhead has made significant progress this year with our pipeline.

Key Points: 
  • Christopher Anzalone, Ph.D., President and CEO at Arrowhead, said: “Arrowhead has made significant progress this year with our pipeline.
  • We now have 14 investigational RNAi-based medicines in the clinic that leverage Arrowhead’s proprietary TRiMTM platform, four of which are in late-stage development.
  • We are excited to launch the 2024 Summer Series of R&D webinars, which will provide an overview of the respective treatment landscapes, the biological rationale and preclinical data supporting each target, and our clinical development strategy for each pipeline program to be highlighted.”
    Each event will be approximately 90 minutes in duration with live webcasts and replays available on the Events and Presentations page under the Investors section of the Arrowhead website.
  • Registration links and additional details regarding times, agendas, and speakers will be provided on the Arrowhead website and social media channels prior to each event.

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Retrieved on: 
星期三, 四月 24, 2024
Science, Research, Pharmaceutical, Public Relations, Investor Relations, General Health, Health, Communications, Clinical Trials, Kidney disease, IgA nephropathy, RNA interference, Arrowhead, Kidney, CFB, RNA, Patient, Liver, System, Translational medicine, Discovery, MBA, Complement factor B, Vaccine

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial ( NCT06209177 ) of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement mediated kidney disease.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial ( NCT06209177 ) of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic, in up to 66 healthy volunteers and patients with complement mediated kidney disease.
  • James Hamilton, M.D., MBA, Chief of Discovery and Translational Medicine at Arrowhead, said: “In preclinical studies, ARO-CFB achieved deep and durable reductions in liver production of complement factor B, which is involved in alternative complement pathway activation and associated with pathogenesis of diseases involving complement activation.
  • ARO-CFB is our second clinical program designed to address diseases associated with activation of the complement pathway, the first being ARO-C3, our Phase 1 program targeting complement component 3.
  • ARO-CFB is being developed as a potential treatment for complement mediated kidney diseases such as immunoglobulin A nephropathy (IgAN), which is the most common glomerular disease worldwide and carries a high lifetime risk of progression to end-stage renal disease.

Digital Ally Announces Multi-Year Agreement with the Kansas City Chiefs

Retrieved on: 
星期一, 四月 8, 2024
Organization, Noise, Digital, Partnership, Arrowhead Stadium, Darkness, Law enforcement, Motion, Wind, EVO, Dust, Ecosystem, Super Bowl, DGLY, Kansas City Chiefs, Arrowhead, Video game

Lenexa, Kansas, April 08, 2024 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (NASDAQ: DGLY) (the “Company”), a leading provider of video solutions which develops, manufactures, and markets advanced video recording products and other critical safety products for law enforcement, emergency management, fleet safety and event security, today announced the signing of a multi-year agreement with the Super Bowl Champion Kansas City Chiefs. The deployment includes 120 FirstVu PRO body cameras, two QuickVu 24-bay docking stations, as well as the utilization of Digital Ally’s EVO Web cloud platform.

Key Points: 
  • The deployment includes 120 FirstVu PRO body cameras, two QuickVu 24-bay docking stations, as well as the utilization of Digital Ally’s EVO Web cloud platform.
  • The continued partnership with Digital Ally underscores the commitment to employing cutting-edge technology to safeguard and enhance the safety and security of stadium staff and attendees during various events hosted at the facility.
  • As part of Digital Ally’s complete ecosystem of video solution products, the FirstVu PRO is compatible with the recently released QuickVu docking station.
  • Digital Ally’s QuickVu system provides a comprehensive and elegant solution for charging, reviewing and offloading video evidence to the cloud.

Brown & Brown, Inc. announces senior leadership team appointments

Retrieved on: 
星期一, 四月 1, 2024
Arrowhead, E&S, Insurance, Brown & Brown, Growth, Management

DAYTONA BEACH, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE:BRO) (the “Company”) has announced the appointment of David Putz and Niels Seebeck to the senior leadership team.

Key Points: 
  • DAYTONA BEACH, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE:BRO) (the “Company”) has announced the appointment of David Putz and Niels Seebeck to the senior leadership team.
  • I am excited to welcome David and Niels to our senior leadership team.
  • Before joining Brown & Brown in 2019, Putz spent nearly 25 years at Zurich Insurance North America, where he was a member of the global leadership team, overseeing alternative markets, including crop, programs, automotive and captives businesses.
  • Niels joined the team in 2015 and is responsible for the growth and oversight of numerous programs, including portfolio management, underwriting and operations.

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Retrieved on: 
星期日, 四月 7, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Arrowhead, Principal, Urinary tract infection, JAMA Cardiology, Apolipoprotein C-III, Risk, Headache, Patient, Hypertriglyceridemia, Diarrhea, COVID-19, American College, APOC3, Pancreatitis, Safety, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).
  • Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels.
  • These data were presented in a late-breaking oral presentation today at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta and simultaneously published in the journal JAMA Cardiology .
  • Subjects treated with plozasiran also showed improvements in multiple atherogenic lipid and lipoprotein levels, including remnant cholesterol, HDL-cholesterol, and non-HDL cholesterol.

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

Retrieved on: 
星期一, 三月 25, 2024
Infectious Diseases, Diabetes, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Arrowhead, Diagnosis, PALISADE, Patient, Hypertriglyceridemia, EAP, Science, Microsoft Access, American College, Clinical trial, RNA interference, FCS, Therapy, Physician, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for patients with familial chylomicronemia syndrome (FCS) who meet certain program eligibility criteria.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for patients with familial chylomicronemia syndrome (FCS) who meet certain program eligibility criteria.
  • Arrowhead will also present new final Phase 2 clinical data from the double-blind portion of the SHASTA-2 study of plozasiran in a late-breaking oral presentation at the upcoming American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24), being held in Atlanta on April 6-8, 2024.
  • “Arrowhead is committed to supporting patients living with various lipid disorders and the physicians who treat them.
  • “Our Phase 3 PALISADE study of plozasiran in patients with FCS is nearing completion and we are further supporting the patient community by initiating an expanded access program for patients and physicians interested in receiving treatment with plozasiran outside of a clinical trial.

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Retrieved on: 
星期五, 三月 8, 2024
Pharmaceutical, Genetics, Health, Clinical Trials, Wheelchair, Myotonia, Cataract, DMPK, Wasting, Exercise, Arrowhead, Conference, DM1, RNA, Muscle weakness, Patient, CUG, Primate, MDA, RNA interference, Episcopal conference, Vaccine

Patients with DM1 have muscle weakness and wasting, myotonia, cataracts, and often develop cardiac conduction abnormalities.

Key Points: 
  • Patients with DM1 have muscle weakness and wasting, myotonia, cataracts, and often develop cardiac conduction abnormalities.
  • Pathogenesis of DM1 is driven by an expanded CUG trinucleotide repeat in the 3’-untranslated region of DMPK transcripts.
  • These abnormal transcripts cause mis-regulated splicing, known as spliceopathy, for certain messenger RNAs which are directly linked to the clinical manifestations of DM1.
  • Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.